CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a safe and effective cell therapy using genome-edited T cells to treat IgA nephropathy, a leading cause of kidney failure. The approach targets specific immune responses and offers potential applications for other autoimmune diseases, ultimately aiming for a one-time treatment option.
There is an increasing prevalence of chronic diseases caused by undesired immune reactions (>10%) with high burden for the both patients (chronicity, organ failure, early death, decreased QoL) and society (EU:>100 bn €/a direct health costs) as current therapies are limited in efficacy and do not reshape sustainably the disturbed immune balance.
Our ultimative goal is to develop a safe and efficient cell therapy based on genome-edited T cells with redirected specificity to sustainably combat IgA…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Freiburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
TECHNISCHE UNIVERSITAET BRAUNSCHWEIG
Germany, Braunschweig
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Norway, Oslo
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Aarhus C
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
